Yifan Pharmaceutical Co., Ltd. (SHE:002019)
China flag China · Delayed Price · Currency is CNY
15.58
+0.59 (3.94%)
Sep 5, 2025, 3:04 PM CST

Yifan Pharmaceutical Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 20202016 - 2020
Period Ending
Jun '25 Dec '24 Dec '23 Jan '23 Jan '22 Dec '20 2016 - 2020
Operating Revenue
5,1405,1404,0443,8194,3795,369
Upgrade
Other Revenue
22.5420.2923.6117.5130.4531.39
Upgrade
5,1635,1604,0683,8374,4095,400
Upgrade
Revenue Growth (YoY)
8.55%26.84%6.03%-12.98%-18.36%4.12%
Upgrade
Cost of Revenue
2,7852,8082,1591,9832,5942,899
Upgrade
Gross Profit
2,3772,3521,9091,8531,8152,501
Upgrade
Selling, General & Admin
1,6181,6291,5031,4351,2971,111
Upgrade
Research & Development
296291.97312.38190.2196.64325.34
Upgrade
Other Operating Expenses
118.5343.5232.3727.0537.2442.11
Upgrade
Operating Expenses
2,0632,0261,9081,6821,5521,487
Upgrade
Operating Income
314.12326.091.09171.35262.681,014
Upgrade
Interest Expense
-61.48-69.1-75.55-85.85-74.59-71.07
Upgrade
Interest & Investment Income
9.248.1213.1321.3925.333.21
Upgrade
Currency Exchange Gain (Loss)
6.05-2.9414.550.19-17.77-18.06
Upgrade
Other Non Operating Income (Expenses)
-11-7.66-14.84-12.38-8.03-3.06
Upgrade
EBT Excluding Unusual Items
256.93254.51-61.68144.69187.59954.93
Upgrade
Impairment of Goodwill
-----11.9-
Upgrade
Gain (Loss) on Sale of Investments
-27.71-14.16-15.06-17.63-4.49-0.01
Upgrade
Gain (Loss) on Sale of Assets
31.8130.152.57-0.5614.83-0.04
Upgrade
Asset Writedown
-14.9-11.48-852.58-102.13-26.34-6.6
Upgrade
Other Unusual Items
193.2129.6557.71132.3751.1132.44
Upgrade
Pretax Income
439.33388.66-869.03156.74210.791,081
Upgrade
Income Tax Expense
4465.0416.6229.65-31.42149.32
Upgrade
Earnings From Continuing Operations
395.33323.62-885.65127.09242.21931.39
Upgrade
Minority Interest in Earnings
41.0662.35334.5864.1336.1837
Upgrade
Net Income
436.39385.97-551.07191.22278.4968.39
Upgrade
Net Income to Common
436.39385.97-551.07191.22278.4968.39
Upgrade
Net Income Growth
----31.31%-71.25%7.19%
Upgrade
Shares Outstanding (Basic)
1,2111,2061,2251,1951,2101,210
Upgrade
Shares Outstanding (Diluted)
1,2111,2061,2251,2751,2101,226
Upgrade
Shares Change (YoY)
-1.09%-1.51%-3.94%5.32%-1.26%0.40%
Upgrade
EPS (Basic)
0.360.32-0.450.160.230.80
Upgrade
EPS (Diluted)
0.360.32-0.450.150.230.79
Upgrade
EPS Growth
----34.78%-70.89%6.76%
Upgrade
Free Cash Flow
163.0812.57-155.5-70.21-270.51392.8
Upgrade
Free Cash Flow Per Share
0.140.01-0.13-0.06-0.220.32
Upgrade
Dividend Per Share
0.1000.200---0.050
Upgrade
Dividend Growth
------50.00%
Upgrade
Gross Margin
46.05%45.59%46.93%48.30%41.16%46.31%
Upgrade
Operating Margin
6.08%6.32%0.03%4.47%5.96%18.77%
Upgrade
Profit Margin
8.45%7.48%-13.55%4.98%6.31%17.93%
Upgrade
Free Cash Flow Margin
3.16%0.24%-3.82%-1.83%-6.13%7.27%
Upgrade
EBITDA
642.14642.69253.66379.13453.821,191
Upgrade
EBITDA Margin
12.44%12.46%6.24%9.88%10.29%22.05%
Upgrade
D&A For EBITDA
328.01316.6252.57207.78191.14177.01
Upgrade
EBIT
314.12326.091.09171.35262.681,014
Upgrade
EBIT Margin
6.08%6.32%0.03%4.47%5.96%18.77%
Upgrade
Effective Tax Rate
10.01%16.73%-18.92%-13.82%
Upgrade
Revenue as Reported
5,1635,1604,0683,8374,4095,400
Upgrade
Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.